SIGA Technologies, Inc. (SIGA)
NASDAQ: SIGA · IEX Real-Time Price · USD
9.64
+0.03 (0.31%)
At close: Jul 23, 2024, 4:00 PM
9.81
+0.17 (1.76%)
After-hours: Jul 23, 2024, 7:06 PM EDT

Company Description

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States.

Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.

The company was incorporated in 1995 and is headquartered in New York, New York.

SIGA Technologies, Inc.
SIGA Technologies logo
Country United States
Founded 1995
IPO Date Sep 9, 1997
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 45
CEO Dr. Diem Nguyen M.B.A., Ph.D.

Contact Details

Address:
31 East 62nd Street
New York, New York 10065
United States
Phone 212-672-9100
Website siga.com

Stock Details

Ticker Symbol SIGA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001010086
CUSIP Number 826917106
ISIN Number US8269171067
Employer ID 13-3864870
SIC Code 2834

Key Executives

Name Position
Dr. Diem Nguyen M.B.A., Ph.D. Chief Executive Officer and Director
Daniel J. Luckshire Executive Vice President, Chief Financial Officer and Secretary
Dr. Dennis E. Hruby Executive Vice President and Chief Scientific Officer
Dr. Jay K. Varma M.D. Executive Vice President, Chief Medical Officer and Director
Tove C. Bolken Senior Vice President of Operations and Chief Supply Chain Officer
Herb Vloedman Senior Vice President and Chief Information Officer
Lawrence R. Miller Esq., J.D. General Counsel

Latest SEC Filings

Date Type Title
Jul 19, 2024 8-K Current Report
Jun 13, 2024 8-K Current Report
May 7, 2024 10-Q Quarterly Report
May 7, 2024 8-K Current Report
Apr 26, 2024 ARS Filing
Apr 26, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2024 DEF 14A Other definitive proxy statements
Apr 1, 2024 8-K Current Report
Mar 12, 2024 10-K Annual Report
Mar 12, 2024 8-K Current Report